TNF-α拮抗剂与托珠单抗治疗大动脉炎的疗效与安全性:209例多中心回顾性研究
该多中心回顾性研究纳入209例大动脉炎患者,评估TNF-α拮抗剂与托珠单抗的疗效与安全性。6个月完全缓解率在TNF-α拮抗剂组为66%、托珠单抗组为70%,两药疗效、复发及药物留存率相当,不良事件发生率无显著差异。
要点
- TNF-α拮抗剂与托珠单抗在难治性大动脉炎中均显示高缓解率。
- 两药6个月完全缓解率、复发率及停药率相当。
- 基线血管体征和泼尼松≥20 mg/天与完全缓解负相关。
核心结论
- TNF-α拮抗剂与托珠单抗对难治性大动脉炎均高效,疗效、复发及药物留存率相当。
研究设计与样本
- 多中心回顾性研究纳入209例大动脉炎患者,其中TNF-α拮抗剂132例(172线),托珠单抗77例(121线)。
主要发现
- 6个月完全缓解:TNF-α拮抗剂组101/152(66%),托珠单抗组75/107(70%)。
- 年龄≥30岁与完全缓解正相关(OR 2.09,95%CI 1.09–3.99),血管体征(OR 0.26,95%CI 0.1–0.65)和基线泼尼松≥20 mg/天(OR 0.51,95%CI 0.28–0.93)负相关。
- 中位随访36个月,103次复发;主动脉弓上分支受累(HR 2.44,95%CI 1.06–5.65)、胸主动脉受累(HR 3.66,95%CI 1.18–11.4)及基线全身症状(HR 2.01,95%CI 1.30–3.11)与复发显著相关。
- 不良事件:TNF-α拮抗剂37例(21%),托珠单抗21例(17%),P=0.4。
临床怎么用
- 对难治性大动脉炎可考虑TNF-α拮抗剂或托珠单抗,两者疗效与安全性相当。
- 基线血管体征、高剂量泼尼松及特定血管受累可能提示缓解率较低或复发风险较高。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK). METHODS: A total of 209 patients with TAK [median age 29 years (interquartile range 7-62)], 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)] or tocilizumab [n = 77 (37%) with 121 lines; i.v. and s.c. in 95 and 26 cases, respectively]. RESULTS: A complete response at 6 months was evidenced in 101/152 (66%) patients on TNF-α antagonists and 75/107 (70%) patients on tocilizumab. Age ≥30 years [odds ratio 2.09 (95% CI 1.09, 3.99)] was associated with complete response, whereas vascular signs [OR 0.26 (95% CI 0.1, 0.65)], baseline prednisone ≥20 mg/day [OR 0.51 (95% CI 0.28, 0.93)] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvement [HR 2.44 (95% CI 1.06, 5.65) and 3.66 (1.18, 11.4), respectively] and systemic signs at baseline [HR 2.01 (95% CI 1.30, 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNF-α antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biologic targeted therapies [37 (21%) on TNF-α antagonists and 21 (17%) on tocilizumab (P = 0.4), respectively]. CONCLUSION: This large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab.
引用
- Mekinian A, Biard L, Dagna L, et al. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology (Oxford). 2022. PMID: 34363461. doi:10.1093/rheumatology/keab635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。